参考文献/References:
[1]Jarrar M,Behl S,Manyam G,et al.Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy[J].Mol Biol Rep,2016,43(6):473-484.[2]Zhou Y,Ingelman-Sundberg M,Lauschke VM.Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects[J].Clin Pharmacol Ther,2017,102(4):688-700.[3]Pereira NL,Geske JB,Mayr M,et al.Pharmacogenetics of Clopidogrel: An Unresolved Issue[J].Circ Cardiovasc Genet,2016,9(2):185-188.[4]Fricke-Galindo I,Céspedes-Garro C,Rodrigues-Soares F,et al.Interethnic variation of CYP2C19 alleles,’predicted’ phenotypes and ’measured’ metabolic phenotypes across world populations[J].Pharmacogenomics J,2016,16(2):113-123.[5]Sibbing D,Koch W,Gebhard D,et al.Cytochrome 2C19*17 allelic variant,platelet aggregation,bleeding events,and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J].Circulation,2010,121(4):512-518.[6]Gurbel PA,Shuldiner AR,Bliden KP,et al.The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy[J].Am Heart J,2011,161(3):598-604.[7]Hulot JS,Collet JP,Silvain J,et al.Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis[J].J Am Coll Cardiol,2010,56(2):134-143.[8]Scott SA,Martis S,Peter I,et al.Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness[J].Pharmacogenomics J,2012,12(4):297-305.[9]刘亚巍,赵小朗,姚璞,等.ABCB1、CYP2C19、CES1基因多态性与缺血性脑卒中患者氯吡格雷抵抗及疗效的关系[J].中国神经免疫学和神经病学杂志,2021,28(2):146-151.[10]Marume K,Hokimoto S,Tabata N,et al.Intraprocedural thrombotic event during coronary intervention depends on CYP2C19 genotype and is a predictor of future clinical event[J].Int J Cardiol,2015,187:231-233.[11]Sugunaraj JP,Palaniswamy C,Selvaraj DR,et al.Clopidogrel resistance[J].Am J Ther,2010,17(2):210-215.[12]Liu G,Yang S,Chen S.The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention[J].Medicine (Baltimore),2020,99(11):e19143.[13]Wang Y,Cai H,Zhou G,et al.Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel[J].J Neurol Sci,2016,369:216-219.[14]Wang Y,Zhao X,Lin J,et al.Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack[J].JAMA,2016,316(1):70-78.[15]Asselbergs FW,Guo Y,van Iperen EP.Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci[J].Am J Hum Genet,2012,91(5):823-838.[16]Jenkins CM,Cedars A,Gross RW.Eicosanoid signalling pathways in the heart[J].Cardiovasc Res,2009,82(2):240-249.[17]Schunck WH,Konkel A,Fischer R,et al.Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases[J].Pharmacol Ther,2018,183:177-204.[18]Apaya MK,Hsiao PW,Yang YC,et al.Deregulating the CYP2C19/Epoxy-Eicosatrienoic Acid-Associated FABP4/FABP5 Signaling Network as a Therapeutic Approach for Metastatic Triple-Negative Breast Cancer[J].Cancers (Basel),2020,12(1):199.[19]Gu S,Sun Y,Han R,et al.Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese[J].BMC Med Genet,2014,15:83.[20]Bai Y,Huang R,Wan L,et al.Association between CYP2C19 gene polymorphisms and lipid metabolism in Chinese patients with ischemic stroke[J].J Int Med Res,2020,48(7):300060520934657.[21]Imig JD.Epoxyeicosatrienoic acids,hypertension,and kidney injury[J].Hypertension,2015,65(3):476-482.[22]Roman RJ.P-450 metabolites of arachidonic acid in the control of cardiovascular function[J].Physiol Rev,2002,82(1):131-185.[23]Fleming I,Busse R.Vascular cytochrome P450 in the regulation of renal function and vascular tone: EDHF,superoxide anions and blood pressure[J].Nephrol Dial Transplant,2001,16(7):1309-1311.[24]Ma Y,Ni W,Zhu W,et al.Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population[J].Blood Press,2011,20(3):166-170.[25]Shin DJ,Kwon J,Park AR,et al.Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans[J].Yonsei Med J,2012,53(6):1113-1119.[26]Morrison HW,Filosa JA.A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion[J].J Neuroinflammation,2013,10:4.[27]Bi C,Fu Y,Li B.Brain-derived neurotrophic factor alleviates diabetes mellitus-accelerated atherosclerosis by promoting M2 polarization of macrophages through repressing the STAT3 pathway[J].Cell Signal,2020,70:109569.[28]Stankovic M,Ljujic B,Babic S,et al.IL-33/IL-33R in various types of carotid artery atherosclerotic lesions[J].Cytokine,2019,120:242-250.[29]Bennett M,Gilroy DW.Lipid Mediators in Inflammation[J].Microbiol Spectr,2016,4(6):MCHD-0035-2016.[30]Bertrand-Thiébault C,Berrahmoune H,Thompson A,et al.Genetic Polymorphism of CYP2C19 gene in the Stanislas cohort.A link with inflammation[J].Ann Hum Genet,2008,72(Pt 2):178-183.
相似文献/References:
[1]余 亮,谭自明,张 斌,等.甘露糖结合凝集素基因多态性与结核病易感性关系的研究[J].医学信息,2018,31(13):65.[doi:10.3969/j.issn.1006-1959.2018.13.019]
YU Liang,TAN Zi-ming,ZHANG Bin,et al.Relationship between Polymorphism of Mannose Binding Lectin Gene and Susceptibility to Tuberculosis[J].Medical Information,2018,31(11):65.[doi:10.3969/j.issn.1006-1959.2018.13.019]
[2]王在川,华 琳.SOD基因多态性与COPD易感性的Meta分析[J].医学信息,2018,31(17):57.[doi:10.3969/j.issn.1006-1959.2018.17.018]
WANG Zai-chuan,HUA Lin.Meta-analysis of SOD Gene Polymorphism and Susceptibility to COPD[J].Medical Information,2018,31(11):57.[doi:10.3969/j.issn.1006-1959.2018.17.018]
[3]邹光美,黄朝任.白介素6基因多态性与多种疾病的相关性研究[J].医学信息,2022,35(12):61.[doi:10.3969/j.issn.1006-1959.2022.12.014]
ZOU Guang-mei,HUANG Chao-ren.Correlation Between Interleukin 6 Gene Polymorphism and Various Diseases[J].Medical Information,2022,35(11):61.[doi:10.3969/j.issn.1006-1959.2022.12.014]
[4]陈启松,何海军,谷光敏,等.IL-6基因多态性与心房颤动相关性的Meta分析[J].医学信息,2020,33(23):73.[doi:10.3969/j.issn.1006-1959.2020.23.021]
CHEN Qi-song,HE Hai-jun,GU Guang-min,et al.Meta Analysis of the Correlation Between IL-6 Gene Polymorphism and Atrial Fibrillation[J].Medical Information,2020,33(11):73.[doi:10.3969/j.issn.1006-1959.2020.23.021]
[5]邓顺顺,平军娇,章 杰,等.APOE基因多态性与精神分裂症的相关性研究[J].医学信息,2023,36(06):110.[doi:10.3969/j.issn.1006-1959.2023.06.024]
DENG Shun-shun,PING Jun-jiao,ZHANG Jie,et al.Study on the Correlation Between APOE Gene Polymorphism and Schizophrenia[J].Medical Information,2023,36(11):110.[doi:10.3969/j.issn.1006-1959.2023.06.024]
[6]张莹莹,郭绪昆,刘 寅.氯吡格雷药代动力学特点及其在心血管疾病中的临床应用[J].医学信息,2021,34(20):45.[doi:10.3969/j.issn.1006-1959.2021.20.011]
ZHANG Ying-ying,GUO Xu-kun,LIU Yin.Pharmacokinetic Characteristics of Clopidogrel and the Clinical Application in Cardiovascular Diseases[J].Medical Information,2021,34(11):45.[doi:10.3969/j.issn.1006-1959.2021.20.011]
[7]赵鑫龙,杨杰孚.华法林药物基因组学的应用[J].医学信息,2021,34(20):50.[doi:10.3969/j.issn.1006-1959.2021.20.012]
ZHAO Xin-long,YANG Jie-fu.Application of Warfarin Pharmacogenomics[J].Medical Information,2021,34(11):50.[doi:10.3969/j.issn.1006-1959.2021.20.012]
[8]郁德波,林志雄,林举达.MAOA基因与精神分裂症的关系研究[J].医学信息,2023,36(16):189.[doi:10.3969/j.issn.1006-1959.2023.16.039]
YU De-bo,LIN Zhi-xiong,LIN Ju-da.Study on the Relationship Between MAOA Gene and Schizophrenia[J].Medical Information,2023,36(11):189.[doi:10.3969/j.issn.1006-1959.2023.16.039]
[9]余 飞,杨丽娜,韦必晓,等.桂西地区人群MTHFR基因多态性及血清同型半胱氨酸水平与不同脑卒中类型发病的相关性[J].医学信息,2023,36(20):103.[doi:10.3969/j.issn.1006-1959.2023.20.019]
YU Fei,YANG Li-na,WEI Bi-xiao,et al.Correlation Between of MTHFR Gene Polymorphism, Serum Homocysteine Levels and Different Types of Stroke in Western Guangxi Population[J].Medical Information,2023,36(11):103.[doi:10.3969/j.issn.1006-1959.2023.20.019]
[10]王 晶,曹名波.非酒精性脂肪肝相关基因多态性的研究进展[J].医学信息,2023,36(24):183.[doi:10.3969/j.issn.1006-1959.2023.24.043]
WANG Jing,CAO Ming-bo.Research Progress on Gene Polymorphisms Related to Non-alcoholic Fatty Liver Disease[J].Medical Information,2023,36(11):183.[doi:10.3969/j.issn.1006-1959.2023.24.043]
[11]朱红涛,丁振江,赵媛媛.CYP2C19基因多态性与氯吡格雷抵抗的相关性研究[J].医学信息,2020,33(08):40.[doi:10.3969/j.issn.1006-1959.2020.08.014]
ZHU Hong-tao,DING Zhen-jiang,ZHAO Yuan-yuan,et al.Correlation Between CYP2C19 Gene Polymorphism and Clopidogrel Resistance[J].Medical Information,2020,33(11):40.[doi:10.3969/j.issn.1006-1959.2020.08.014]